Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2018 | 12 | 0.720 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2019 | 4 | 0.620 |
Why?
|
| Hand-Foot Syndrome | 1 | 2018 | 2 | 0.610 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 6 | 0.610 |
Why?
|
| Pancreatitis | 1 | 2019 | 39 | 0.600 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 37 | 0.580 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 109 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 534 | 0.400 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 28 | 0.390 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 39 | 0.300 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 42 | 0.290 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 11 | 0.290 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 16 | 0.290 |
Why?
|
| Recurrence | 2 | 2019 | 323 | 0.280 |
Why?
|
| Middle Aged | 6 | 2023 | 7164 | 0.210 |
Why?
|
| Humans | 14 | 2023 | 28121 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 82 | 0.180 |
Why?
|
| Female | 9 | 2023 | 15156 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 113 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2018 | 2380 | 0.160 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2018 | 2 | 0.150 |
Why?
|
| Male | 9 | 2023 | 13487 | 0.150 |
Why?
|
| Adult | 6 | 2023 | 7757 | 0.150 |
Why?
|
| Acute Disease | 1 | 2019 | 158 | 0.150 |
Why?
|
| Sarcoma, Myeloid | 1 | 2018 | 7 | 0.150 |
Why?
|
| Smoothened Receptor | 1 | 2018 | 8 | 0.150 |
Why?
|
| Anilides | 1 | 2018 | 19 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 22 | 0.150 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 15 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 162 | 0.150 |
Why?
|
| Neck | 1 | 2018 | 26 | 0.150 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 13 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 144 | 0.140 |
Why?
|
| Ploidies | 1 | 2017 | 6 | 0.140 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2017 | 3 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2018 | 103 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 37 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 124 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 108 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 105 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 283 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 473 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 153 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 329 | 0.130 |
Why?
|
| Young Adult | 2 | 2023 | 2731 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 477 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 354 | 0.110 |
Why?
|
| Obesity | 1 | 2018 | 668 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 678 | 0.100 |
Why?
|
| Aged | 3 | 2023 | 5416 | 0.060 |
Why?
|
| SEER Program | 1 | 2023 | 47 | 0.050 |
Why?
|
| Adolescent | 2 | 2023 | 3123 | 0.050 |
Why?
|
| Standard of Care | 1 | 2022 | 12 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 70 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 42 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 27 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 17 | 0.050 |
Why?
|
| Rituximab | 1 | 2022 | 63 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2022 | 63 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 77 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 179 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 193 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2018 | 21 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 25 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 411 | 0.040 |
Why?
|
| Species Specificity | 1 | 2018 | 191 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 67 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 110 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 112 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 76 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 194 | 0.040 |
Why?
|
| Platelet Count | 1 | 2018 | 111 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 207 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2018 | 118 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 2021 | 0.040 |
Why?
|
| Body Weight | 1 | 2018 | 250 | 0.040 |
Why?
|
| Age of Onset | 1 | 2017 | 71 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 605 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 158 | 0.030 |
Why?
|
| Diet | 1 | 2018 | 231 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 804 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 803 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1324 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 10399 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1570 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 1433 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 818 | 0.020 |
Why?
|